SCHEMBL4673318

SCHEMBL4673318

O=C(O)C(O)=CC(=O)c1coc(Cc2ccccn2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.39
ALDH1A1 P00352 6/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
HTT P42858 1/20 0.39
POLB P06746 4/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HIF1A Q16665 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 4/20 0.36
KMT2A Q03164 3/20 0.36
MAPK1 P28482 1/20 0.36
PTPRA P18433 1/20 0.36
IDO1 P14902 1/20 0.36
MEN1 O00255 2/20 0.35
NPC1 O15118 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673313 1.00 KDM4E (0.39) KDM4EALDH1A1L3MBTL1HTTPOLB
SCHEMBL4674726 0.82 IDH1 (0.49) LMNAHSD17B10
SCHEMBL4674730 0.82 IDH1 (0.49) LMNAHSD17B10
SCHEMBL5899363 0.80 ALDH1A1 (0.34) KDM4EALDH1A1L3MBTL1HTTPOLB
SCHEMBL4680836 0.80 KDM4E (0.34) KDM4EALDH1A1L3MBTL1HTTPOLB
SCHEMBL4674466 0.79 POLB (0.39) KDM4EALDH1A1L3MBTL1HTTPOLB
SCHEMBL4674461 0.79 POLB (0.39) KDM4EALDH1A1L3MBTL1HTTPOLB
SCHEMBL4671554 0.79 IDH1 (0.37) KDM4EALDH1A1HPGDRAB9AMAPK1
SCHEMBL4671548 0.79 IDH1 (0.37) KDM4EALDH1A1HPGDRAB9AMAPK1
SCHEMBL4673653 0.78 ALDH1A1 (0.38) KDM4EALDH1A1L3MBTL1HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM4E 947/4885ALDH1A1 980/4885L3MBTL1 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.